HC Wainwright Lifts Earnings Estimates for PDS Biotechnology

Key Points

• HC Wainwright increased its Q3 2025 earnings per share forecast for PDS Biotechnology from ($0.26) to ($0.25), while maintaining a "Buy" rating and a price target of $13.00.
• PDS Biotechnology’s stock rose 3.4% to a trading price of $1.20, with a market capitalization of $54.85 million.
• Institutional investors hold approximately 26.84% of PDS Biotechnology’s stock, with significant recent purchases by firms like Raymond James and Two Sigma Investments.

PDS Biotechnology Corporation (NASDAQ:PDSB - Free Report) - Research analysts at HC Wainwright raised their Q3 2025 EPS estimates for shares of PDS Biotechnology in a research report issued on Wednesday, August 13th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.25) for the quarter, up from their prior forecast of ($0.26). HC Wainwright has a "Buy" rating and a $13.00 price target on the stock. The consensus estimate for PDS Biotechnology's current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for PDS Biotechnology's FY2025 earnings at ($0.96) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($1.01) EPS and FY2028 earnings at ($0.83) EPS.

Separately, Wall Street Zen lowered shares of PDS Biotechnology from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. One investment analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. According to data from MarketBeat.com, PDS Biotechnology currently has an average rating of "Buy" and an average target price of $10.00.

PDS Biotechnology Stock Performance

Shares of PDSB stock traded up $0.0250 during trading hours on Friday, reaching $1.1950. 93,798 shares of the company's stock were exchanged, compared to its average volume of 535,172. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.92 and a quick ratio of 2.92. The company's 50 day moving average is $1.30 and its two-hundred day moving average is $1.31. The company has a market cap of $55.72 million, a P/E ratio of -1.30 and a beta of 0.95. PDS Biotechnology has a 1 year low of $0.85 and a 1 year high of $4.29.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.03.

Institutional Investors Weigh In On PDS Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC acquired a new stake in shares of PDS Biotechnology during the first quarter valued at $5,259,000. Blair William & Co. IL lifted its holdings in PDS Biotechnology by 63.3% in the 1st quarter. Blair William & Co. IL now owns 257,200 shares of the company's stock valued at $306,000 after purchasing an additional 99,700 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of PDS Biotechnology by 331.0% during the 4th quarter. Renaissance Technologies LLC now owns 100,000 shares of the company's stock worth $163,000 after purchasing an additional 76,800 shares during the last quarter. Iron Gate Global Advisors LLC purchased a new stake in shares of PDS Biotechnology during the first quarter worth about $89,000. Finally, Jane Street Group LLC acquired a new position in shares of PDS Biotechnology in the second quarter valued at approximately $92,000. Hedge funds and other institutional investors own 26.84% of the company's stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.